Key statistics
As of last trade, Gyre Therapeutics Inc (L9S:DUS) traded at 11.30, 26.26% above the 52 week low of 8.95 set on Aug 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.10 |
---|---|
High | 11.30 |
Low | 11.10 |
Bid | 10.80 |
Offer | 11.20 |
Previous close | 11.50 |
Average volume | 24.00 |
---|---|
Shares outstanding | 93.42m |
Free float | 23.63m |
P/E (TTM) | -- |
Market cap | 1.10bn USD |
EPS (TTM) | -0.2281 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:30 GMT.
More ▼
Announcements
- Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
- Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
- Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
- Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
- Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
- Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
- Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
- Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
- Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
More ▼